This dataset contains WES data 5 patients and WGS data of 1 patient with Lynch Syndrome from the INFORM registry.
This dataset contains paired whole exome sequence data of 5 patients (control/tumor pairs) and paired whole genome sequencing data of 1 patient (control/tumor pair) with Lynch Syndrome from the INFORM registry. Paired sequencing was done mostly on Illumina HiSeq 4000, few on HiSeq2500 and NovaSeq 6000. The library preparation was either with Agilent SureSelect Human_All_Exon V5 (hg19) or with Agilent SureSelectXT HS Human_All_Exon V7 (hg19). The WGS samples were prepared with Agilent SureSelect WGS.
- 13 samples
- DAC: EGAC00001003315
- Technologies: Illumina HiSeq 2500, Illumina HiSeq 4000, Illumina NovaSeq 6000
Inform Policy for Data Access for the submission of Lynch syndrome data
Data Protection Agreement (DPA) - Commitment to data privacy protection for the usage of molecular data in academic research I undertake to use the sequence data of patient IXXX-XXX obtained in the context of the INFORM registry, exclusively for academic research purposes, as stated in the patient informed consent. Research activities include studies of molecular, genetic, immunological, and other features of the tumor disease, as well as the development of new therapeutic options or diagnostic methods where appropriate. I have presented the research project „please write here the name of the project“ to the respective GPOH study group chairs and/or national coordinators and to the INFORM Data Access Committee. Further, I have received professional legal advice and/or a positive vote from the Ethics Committee. Prior to publication, the INFORM coordinators will be asked for their approval. For this purpose, the manuscript is submitted to the INFORM coordinators for review at least 4 weeks before submission for publication. I understand that the INFORM IDs of the form IXXX-XXX are for internal use only, and must not be published. I will confirm the publication IDs with the INFORM coordinators in advance. All applicable data protection laws will be respected. Genetic data will be encoded and stored separately from clinical data. I ensure that these data at our institution are protected against access by any third parties. The data will not be disclosed to unauthorized third parties. Equally, the codes necessary for re-identification will not be disclosed to unauthorized third parties. No attempt will be made to identify the respective patient via their genetic or any other data. Future publications will be prepared in a way that does not allow any conclusion regarding the person’s identity.
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| EGAS00001007146 | Other |
This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.